SanBio Inc.
Basic information
- Head office
- 13F, St. Luke's Tower, 8-1 Akashicho, Chuo-ku, Tokyo 104-0044, Japan
- Chief executive
- Keita Mori
- Capital
- 8,375,000,000 (83 100 million)
- Employees (non-consolidated)
- 29 people
- Employees (consolidated)
- 33 people
- Start date
- 2013-02-01
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
| NeurologyLive | ||||||||
|
|
||||||||
| Shared Research Latitude Inc. | ||||||||
|
|
||||||||
| OCUMENSION (HONG KONG) LIMITED | ||||||||
| RX Japan | ||||||||
|
|
||||||||
|
|
||||||||
|
|
Network
History
Received transfer of intellectual property related to the basic seeds that are the core technology of current development products from Yokohama TLO Corporation.![]()
SB623 Designated as a target item for the FDA's RMAT in the field of chronic traumatic brain injury.![]()
Signed option agreement with Daiichi Sankyo Company, Limited for SB623 in the US and Canada for stroke![]()
Dissolution of joint development and license agreement with Sumitomo Dainippon Pharma Co., Ltd. for the use of SB623 in chronic stroke in the United States and Canada.![]()
Completed patient dosing in Phase 1/2a clinical trial of SB623 for stroke in the US. Moved headquarters of SanBio Inc. to Minato-ku, Tokyo![]()
Completed administration to patients in the United States for Phase 1/2a clinical trials of SB623 for stroke.![]()
Reported results of Phase 1/2a clinical trial of SB623 for stroke at the International Stroke Conference 2014 in San Diego, USA (Professor Gary Steinberg, Chief of Neurosurgery at Stanford University, clinical trial director)![]()
Received approval from the US FDA for completion of Phase 1/2a and initiation of Phase 2b for SB623 in chronic stroke![]()
Signed joint development and licensing agreement with Daiichi Sankyo Company, Limited for SB623 in the US and Canada for chronic stroke![]()
In the field of traumatic brain injury, the Pharmaceuticals and Medical Devices Agency (PMDA) accepts clinical trial notification for a Japan-U.S. global clinical trial (Phase 2).![]()
Enrollment of the first subjects in the United States for a Phase 2 clinical trial in the field of traumatic brain injury (SB623).![]()
Enrollment of the first subjects in Japan for a Phase 2 clinical trial in the field of traumatic brain injury (SB623).![]()
Received a total of 20 million dollars in grants from the California Institute for Regenerative Medicine (CIRM) for a Phase 2b clinical trial for stroke.![]()
Completion of patient enrollment in the United States for a Phase 2b clinical trial of SB623 for chronic stroke.![]()
Agreement to terminate the exclusive license agreement with Teijin Limited for the use of SB623 in Japan for chronic stroke.![]()
Completion of patient enrollment in Japan and the United States for a Phase 2 clinical trial of SB623 for chronic traumatic brain injury.![]()
SB623 Designated as a pioneering review system target item as a regenerative medicine product by the Ministry of Health, Labour and Welfare![]()
News
Public records
National Tax Agency basic information6010601044067
- Trade name
- サンバイオ株式会社
- Trade name (kana)
- サンバイオ
- Name in English
- Corporation type
- 301
- Address
- 〒104-0044 東京都中央区明石町8番1号
- Postal code
- 1040044
- Prefecture code
- 13
- City code
- 102
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2015-10-05
- Update date
- 2018-07-23
- Change date
- 2015-10-05
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 01
- Correction type
- 1
- Trade name image ID
- Address image ID
- Sequence number
- 2064149
METI gBizINFO6010601044067
- Corporate number
- 6010601044067
- Trade name
- サンバイオ株式会社
- Trade name (kana)
- サンバイオ
- Trade name (alphabet)
- Registry closure date
- Reason for registry closure
- Registered address
- 東京都中央区明石町8番1号
- Postal code
- 1040044
- Prefecture
- 東京都
- Prefecture code
- 13
- City or district
- 中央区
- City code
- 102
- Street address
- 明石町8番1号
- Organisation type
- 301
- Processing type
- 01
- Correction type
- 1
- Status
- Representative
- 代表取締役社長 森 敬太
- Capital
- 8375431000
- Employees
- 33
- Employees (male)
- Employees (female)
- Business summary
- Website URL
- Year founded
- Business category
- Date established
- Unified government qualification - grade
- Unified government qualification - business items
- Update date
- 2018-07-23
- Key information
- 6010601044067